Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer

Faculty

Sara Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Statement of Need

Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents, which may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether.

In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Evaluate unmet needs in the management of HER2- mBC, including expanding treatment options for those who have progressive disease and the implementation of policies to promote equitable care
  • Select patients with HER2- mBC, who have progressed despite prior treatment, to receive ADC-based regimens based on guidelines, expert consensus, and latest clinical trial findings
  • Integrate strategies to monitor for and manage AEs in patients receiving ADCs for HER2- mBC

Financial Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Target Audience

Community oncologists and their interprofessional team of pharmacists, nurses, nurse practitioners (NPs), and physician associates (PAs)

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Council for Pharmacy Education

This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-24-009-L01-P).

American Nurses Credentialing Center

This activity is designated for 1.00 contact hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

American Nurses Credentialing Center with ILNA

This activity is designated for 1.00 contact hours.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

 

OCN® 

  • ​​Care Continuum (Screening, Survivorship/EoL)
  • ​​Oncology Nursing Practice (Scientific Basis/Profession)
  • Symptom Management & Palliative Care
  • Psychosocial Dimensions of Care


AOCNP®/AOCNS® 

  • Cancer Treatment
  • ​​Side Effect & Symptom Management
  • ​​Psychosocial Issues
  • ​​Professional Practice


CPHON® 

  • Cancer Treatment
  • ​​Side Effect & Symptom Management
  • Psychosocial Issues


BMTCN® 

  • Professional Performance


CBCN® 

  • ​​Coordination of Care (Breast Health, Screening, Early Detection/Survivorship)
  • ​​Diagnosis & Staging
  • ​​Nursing Practice (Symptom Management, EoL Care, Professional)
  • ​​Psychosocial & Spiritual

 

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 01/15/2025. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Tolaney reports the following financial relationships:

Consultant/Advisory Board (not leadership): Aadi Biosciences; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer; Blueprint Medicines Corporation; Bristol Myers Squibb Company; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; eFFECTOR; Eisai Inc.; Eli Lilly and Company; Genentech, Inc./Roche; Gilead Sciences, Inc.; Hengrui USA; Incyte; Infinity Therapeutics; Jazz Pharmaceuticals, Inc.; Menarini/Stemline Therapeutics, Inc.; Merck & Co., Inc.; Natera, Inc.; Novartis Pharmaceuticals Corporation; OncXerna Therapeutics, Inc.; Pfizer Inc.; Reveal Genomics; Sanofi; Seattle Genetics; Inc.; Sumitovant Biopharma, Inc.; SystImmune, Inc.; Tango Therapeutics; Umoja Biopharma; Zentalis Pharmaceuticals; and Zymeworks Inc.

Research Support (paid to institution):  AstraZeneca; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; Pfizer Inc.; and Seattle Genetics, Inc.

Other financial or material support:
Travel Support: Eli Lilly and Company; Sanofi; Gilead Sciences, Inc.; and Jazz Pharmaceuticals, Inc.

The following individuals have no financial relationships to disclose: 

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

GR-037

Call us at 859-260-1717  •  info@ceconcepts.com

Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer
Activity Date: 11/15/2024 at 12:00 PM EST